Transforming approaches to treating TRK fusion cancer: historical comparison of Larotrectinib and histology-specific therapies.
CONCLUSIONS: Utilizing larotrectinib as a case example across these types of historical comparisons shows that larotrectinib provides positive efficacy outcomes in TRK fusion cancer across tumor histologies known to harbor NTRK gene fusions that may be preferable to historical treatments.
PMID: 33148054 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Colorectal Cancer | Fibrosarcoma | Genetics | Glioma | History of Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Pediatrics | Research | Salivary Gland Cancer | Sarcomas | Soft Tissue Sarcoma | Thyroid | Thyroid Cancer